Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
|
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA 2021 |
| gptkbp:ATCCode |
J06BD09
|
| gptkbp:brand |
gptkb:Xevudy
|
| gptkbp:CASNumber |
2464506-77-8
|
| gptkbp:developedBy |
gptkb:Vir_Biotechnology
GlaxoSmithKline |
| gptkbp:halfLife |
49 days
|
| gptkbp:hasMolecularFormula |
C6518H10008N1732O2032S46
|
| https://www.w3.org/2000/01/rdf-schema#label |
Sotrovimab
|
| gptkbp:indication |
mild to moderate COVID-19
patients at high risk of severe COVID-19 |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
neutralizes SARS-CoV-2
|
| gptkbp:notRecommendedFor |
hospitalized patients requiring oxygen
|
| gptkbp:origin |
human monoclonal antibody
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
fever
nausea diarrhea shortness of breath chills rash allergic reactions |
| gptkbp:target |
gptkb:SARS-CoV-2_spike_protein
|
| gptkbp:UNII |
6Q1K1Y1LMX
|
| gptkbp:usedFor |
gptkb:COVID-19
|
| gptkbp:bfsParent |
gptkb:Vir_Biotechnology
|
| gptkbp:bfsLayer |
6
|